A Phase 3 Multicenter, Randomized, Placebo-controlled, Double-blind Study to Evaluate the Efficacy and Safety of Eneboparatide (AZP-3601), a Parathyroid Hormone Receptor Agonist, in Patients With Chronic Hypoparathyroidism (CALYPSO)

Status: Active, no longer recruiting

Phase of Trial: Phase III

Latest Information Update: 19 Mar 2025

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Eneboparatide (Primary)
Indications Hypoparathyroidism
Focus Registrational; Therapeutic Use
Acronyms CALYPSO
Sponsors Amolyt Pharma; AstraZeneca

Most Recent Events

17 Mar 2025 Primary endpoint(normalising serum calcium in adults with hypoparathyroidism at 24 weeks ) has been met, as per AstraZeneca media release.
17 Mar 2025 Results published in the AstraZeneca Media Release
15 Jul 2024 According to an Amolyt Pharma media release, Amolyt Pharma has been acquired AstraZeneca.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com

Welcome to AdisInsight